TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03962907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine, Lifo-Scrub sol 4%®, 500ml, B. Braun
Description: 5 - day decolonization procedure prior elective surgery. In carriers with Chlorhexidine daily showers and Mupirocin twice a day nasal ointment. In non-carriers Chlorhexidine showers will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine, Lifo-Scrub sol 4%®, 500ml, B. Braun
Description: 5 - day decolonization procedure prior elective surgery. In carriers with Chlorhexidine daily showers and Mupirocin twice a day nasal ointment. In non-carriers Chlorhexidine showers will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BACTROBAN® Nasal ong
Description: Mupirocin, BACTROBAN® Nasal ong, 3g, GSK
Study: NCT00037440

Intervention type: GENETIC
Intervention: Polymorphisms measured

Intervention type: GENETIC
Intervention: Polymorphisms measured
Study: NCT05197933

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Description: Laparoscopic resection for GIST at unfavorable anatomic site of stomach will be conducted
Study: NCT03292874

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: high resolution MRI (hrMRI)
Description: high resolution MRI (hrMRI) and standard MRI (sMRI) will be obtained at baseline and again in approximately 1 year in patients on prostate cancer active surveillance.
Study: NCT02761473

Intervention type: OTHER
Intervention: skin biopsy
Description: A skin biopsy will be obtained from a typical UP lesion in affected patients

Intervention type: OTHER
Intervention: blood draw
Description: Blood will be obtained from subjects, parents and unaffected siblings
Study: NCT03304041

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low-FODMAPs diet
Description: The low-FODMAPs diet(LFD) aims to keep oligosaccharides, fructose in excess of glucose, and polyol content at less than 0.5 g each per serving based on previously published data.~low-FODMAPs diet therapy for 3 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Traditional dietary advice
Description: Traditional dietary advice(TDA) will focus more on how and when to eat rather than on what foods to ingest . Patients will be instructed to regularly eat, never too much or too little, never to be hungry or too full; to eat in peace and to chew thoroughly; reduce intake of fatty, spicy food, fiber, coffee and alcohol during the intervention period~traditional dietary advice for 3 weeks
Study: NCT01727375

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circadian light
Description: Artificial ceiling lighting throughout the day will be provided by the Philips HealWell system, CE marked, which is able to deliver varying light levels and warmer or cooler light according to the time of the day (circadian light). Emergency or examination lighting can be set on demand as circumstances require.~Lighting conditions at the patients bedside will be characterized by transformations on the time-series of light levels as measured by a luxmeter. The following metrics will be used for lighting characterization in a period of 24h: mean levels of bright and dark periods, contrast between bright and dark periods, clustering of bright and dark periods, and circadian variation.
Study: NCT00358319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Karenitecin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Karenitecin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Study: NCT01135888

Intervention type: DEVICE
Intervention: Skin cooling devices
Description: Cooling vest and cooling bandana

Intervention type: DEVICE
Intervention: Skin cooling devices
Description: Cooling vest and cooling bandana
Study: NCT01999842

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational H7N9 vaccine GSK3206641A
Description: One dose of GSK3206641A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of arm at Day 0 and the second dose of GSK3206641A H7N9 vaccine administered IM in the deltoid region of arm at Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational H7N9 vaccine GSK3206641A
Description: One dose of GSK3206641A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of arm at Day 0 and the second dose of GSK3206641A H7N9 vaccine administered IM in the deltoid region of arm at Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational H7N9 vaccine GSK3206641A
Description: One dose of GSK3206641A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of arm at Day 0 and the second dose of GSK3206641A H7N9 vaccine administered IM in the deltoid region of arm at Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational H7N9 vaccine GSK3206641A
Description: One dose of GSK3206641A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of arm at Day 0 and the second dose of GSK3206641A H7N9 vaccine administered IM in the deltoid region of arm at Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational H7N9 vaccine GSK3206640A
Description: One dose of GSK3206640A H7N9 vaccine administered IM at the deltoid region of arm at Day 0 and the second dose of GSK3206640A H7N9 vaccine administered IM at the deltoid region of arm at Day 21

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of placebo administered IM at the deltoid region of arm at Day 0 and the second dose of placebo administered IM at the deltoid region of arm at Day 21
Study: NCT03556085

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venous sinus stenting (Serenity River)
Description: Patient is placed under general anesthesia. From femoral vein access, a standard guide-catheter is advanced in the internal jugular vein (on the side considered for stenting). The sigmoid then transverse sinus is catheterized with a microcatheter and guide-wire and an exchange guide-wire is placed in the superior sagittal sinus. The River stent delivery catheter is advanced over the exchange guide-wire in the sigmoid then transverse sinus up to the torcula. The River stent is deployed to cover the entire transverse sinus and the proximal half of the sigmoid sinus. The catheters are removed and hemostasis obtained by using a closure device or manual compression. The patient is kept overnight in the hospital for observation.
Study: NCT05121467

Intervention type: OTHER
Intervention: Pain Assessment
Description: Visual Analogue Scale (VAS) were included in the study

Intervention type: OTHER
Intervention: Assessment of Muscular Endurance
Description: The endurance of the 9 muscles/muscle groups including cervical flexor, extensor, deep flexor muscles, trunk flexor, extensor, lateral flexor, and stabilizer muscles, upper extremity, and scapular muscles (mm. serratus anterior and trapezius) were evaluated based on the assessment instructions given in the studies of Edmonston et al., Grimmer et al., Evans et al., Reece et al., ACSM guideline

Intervention type: OTHER
Intervention: Assessment of Neck Awareness
Description: The Turkish version of the Fremantle Neck Awareness Questionnaire (FreNAQ) which was developed by Wand et al. to assess neck awareness in patients with chronic neck pain was used in this study

Intervention type: OTHER
Intervention: Assessment of Fear of Movement
Description: The fear of movement was assessed by the Turkish version of the Tampa Scale of Kinesiophobia which originally developed by Kori et al.
Study: NCT05299346

Intervention type: OTHER
Intervention: Follow up
Description: Comprehensive follow up in dedicated follow up unit
Study: NCT02355236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen/Esomeprazol 500/20mg
Description: Tablet, b.i.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200mg
Description: Capsule, o.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naxozol-Placebo
Description: Tablet (which is identical to Naxozol), b.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator-Placebo
Description: Capsule (which is identical to Celebrex), o.d.
Study: NCT04164784

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: therapeutic monitoring
Description: According to the glucose lever recorded by FreeStyle Libre H (Flash Continuous Glucose Monitoring System) ,the investigators give the intervention group instructions to adjust their diet and lifestyle to abtain a good glucose control.
Study: NCT00856986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Metformin tablets, at least 1500 mg/day
Study: NCT01179984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bard® LifeStent® Vascular Stent System
Description: Stent Implantation
Study: NCT04177537

Intervention type: DEVICE
Intervention: Low Intensity Continuous Ultrasound
Description: 3MHz, 0.132W/cm2, 1.3W for 4 hours day delivered by an acoustic device provided by Zetroz Systems LLC
Study: NCT02462187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVN1000 8% Gel
Description: once and twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVN1000 8% Gel
Description: once and twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVN1000 16%
Description: once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVN1000 24%
Description: once daily
Study: NCT01558115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: The dose of denosumab is 60 mg every 6 months by subcutaneous injection.~The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2.~Group # 1: Receive active drug for year 1 and year 2 of the study~Group #2: Receive placebo for year 1 and active drug for year 2 of the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Denosumab
Description: The dose of denosumab is 60 mg every 6 months by subcutaneous injection.~The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2.~Group # 1: Receive active drug for year 1 and year 2 of the study~Group #2: Receive placebo for year 1 and active drug for year 2 of the study

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The dose of denosumab is 60 mg every 6 months by subcutaneous injection. The placebo group will receive vehicle injections at the same time interval.~The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2.~Group # 1: Receive active drug for year 1 and year 2 of the study~Group #2: Receive placebo for year 1 and active drug for year 2 of the study
Study: NCT02661204

Intervention type: DEVICE
Intervention: Automated breast ultrasound examination (ABUS)
Description: Automated breast ultrasound examination

Intervention type: DEVICE
Intervention: Automated breast ultrasound examination (ABUS)
Description: Automated breast ultrasound examination

Intervention type: DEVICE
Intervention: Automated breast ultrasound examination (ABUS)
Description: Automated breast ultrasound examination

Intervention type: DEVICE
Intervention: Automated breast ultrasound examination (ABUS)
Description: Automated breast ultrasound examination
Study: NCT01195818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAS Inhibitors
Description: Clinical trial testing the effect of RAS inhibitors (Ramipril or Irbesartan)on sickle cell disease patients wit hyperfiltration and albuminuria for a six month period followed by one month wash out period. Drug will be given after the first GFR measurement on a daily basis with a full dose given after the first month.
Study: NCT04054206

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MN-166
Description: MN-166 (ibudilast) is an orally available small molecule drug currently being investigated for human treatment in multiple sclerosis, amyotrophic lateral sclerosis, glioblastoma, and alcohol and drug use disorders.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MN-166
Description: MN-166 (ibudilast) is an orally available small molecule drug currently being investigated for human treatment in multiple sclerosis, amyotrophic lateral sclerosis, glioblastoma, and alcohol and drug use disorders.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MN-166
Description: MN-166 (ibudilast) is an orally available small molecule drug currently being investigated for human treatment in multiple sclerosis, amyotrophic lateral sclerosis, glioblastoma, and alcohol and drug use disorders.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MN-166
Description: MN-166 (ibudilast) is an orally available small molecule drug currently being investigated for human treatment in multiple sclerosis, amyotrophic lateral sclerosis, glioblastoma, and alcohol and drug use disorders.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MN-166
Description: MN-166 (ibudilast) is an orally available small molecule drug currently being investigated for human treatment in multiple sclerosis, amyotrophic lateral sclerosis, glioblastoma, and alcohol and drug use disorders.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MN-166
Description: MN-166 (ibudilast) is an orally available small molecule drug currently being investigated for human treatment in multiple sclerosis, amyotrophic lateral sclerosis, glioblastoma, and alcohol and drug use disorders.
Study: NCT02140970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 10 mg/kg orally up to a maximum of 400 mg given once at least 15 minutes prior to ureteral stent removal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar-tasting and appearing liquid placebo of equal volume to be given once orally at least 15 minutes prior to ureteral stent removal
Study: NCT04199065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Good Practice Guidelines implementation
Description: Implementation of Good Practice Guidelines on the framework of the Best Practice Spotlight Organization in Spain (CCEC® / BPSO®), that allows a standardized methodology for providing care and registering indicators.
Study: NCT04106128

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultrasound examination
Description: Measuring the thickening fraction by diaphragmatic ultrasound of acute diaphragmatic dysfunction in patients admitted for acute respiratory distress
Study: NCT02575729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: betamethasone
Description: Inject betamethasone on the wrist for patient with carpal tunnel syndrome with sonography- guided, directly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: betamethasone
Description: Inject betamethasone on the wrist for patient with carpal tunnel syndrome with sonography- guided, directly.
Study: NCT00634140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe
Description: ezetimibe 10 mg daily for 4 to 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo for 4-6 weeks
Study: NCT04487392

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrogen vaginal cream group (group A)
Description: The participants selected for group A will be provided with estriol 0.01% vaginal cream, which should be applied at home: 1 intravaginal applicator at night, daily for 2 weeks, followed by 2 times a week, on alternate days (Monday - Thursday) for another 2 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photobiomodutation group (group B)
Description: The participants selected for group B will be undergo photobiomodulation with red LED. With the participant in the lithotomy position, the speculum will be introduced into the vaginal canal and a vaginal wash with 0.9% saline will be performed to remove secretions. Afterwards, the speculum will be removed and the device with a red LED inserted up to about 6 cm from the introitus. A non-lubricated condom will be used in the LED device for patient protection. Sessions will take place once a week for 4 weeks.
Study: NCT03435484

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm A
Description: Intervention includes various iterations of instructions for completing the Health Assessment Questionnaire. Participants in this group will receive one version (out of two) of instructions for completing the Health Assessment Questionnaire.
Study: NCT03220646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abemaciclib
Description: abemaciclib 200mg PO q12 hours (+/- 2 hours) on days 1-28 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abemaciclib
Description: abemaciclib 200mg PO q12 hours (+/- 2 hours) on days 1-28 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abemaciclib
Description: 200mg PO q12 hours (+/- 2 hours) for 4-7 days prior to surgery. Upon recovery from surgery, patients will resume abemaciclib at the same dose and schedule as cohorts A and C.
Study: NCT00430989

Intervention type: OTHER
Group type: OTHER
Intervention: Nitrous Oxide
Description: General anaesthesia with the inclusion of Nitrous Oxide at 70%

Intervention type: OTHER
Group type: OTHER
Intervention: No Nitrous Oxide
Description: General anaesthesia with no use of Nitrous Oxide
Study: NCT04687293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HUBER (LPG Systems, France)
Description: The HUBER® device consists of an oval motorized platform, which performs rotating, oscillatory movements with a controlled amplitude and speed. It also comprises, two large handles with force sensors, mounted on a movable column. Its originality is based on its capacity to capture simultaneously the subjects' balance, core stability, core strength and total body strength; and adapt the training accordingly. Indeed, the platform interferes with the balance of the patient who must continually adjust his/her posture by exerting isometric pushing and pulling efforts with the arms. As a result, the device provides postural and muscle adaptation with visual feedback. Due to the constant adaptation of the device, it is thought to enhance muscular strength and improve neuromuscular coordination simultaneously.
Study: NCT01833494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21
Study: NCT03056235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELAPR002f
Description: 30mg/ml Tropoelastin cross-linked with derivatised hyaluronic acid

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline control
Study: NCT00585988

Intervention type: DEVICE
Group type: OTHER
Intervention: Hip Resurfacing System
Description: This arm will utilize a hip resurfacing system.

Intervention type: DEVICE
Group type: OTHER
Intervention: M2a-Magnum™ Large Metal Articulation
Description: This arm will utilize the M2a-Magnum™ implant system.
Study: NCT00603941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-7017
Description: At Phase 1, CS-7017 will be tested in combination with paclitaxel at the following dosage levels: 0.15, 0.30, or 0.50 mg BID. At Phase 2, CS-7017 will be administered at the recommended phase 2 dose (RP2D).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-7017
Description: At Phase 1, CS-7017 will be tested in combination with paclitaxel at the following dosage levels: 0.15, 0.30, or 0.50 mg BID. At Phase 2, CS-7017 will be administered at the recommended phase 2 dose (RP2D).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-7017
Description: At Phase 1, CS-7017 will be tested in combination with paclitaxel at the following dosage levels: 0.15, 0.30, or 0.50 mg BID. At Phase 2, CS-7017 will be administered at the recommended phase 2 dose (RP2D).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Commercially available paclitaxel will be administrated as IV infusion over 3 hours once every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Commercially available paclitaxel will be administrated as IV infusion over 3 hours once every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Commercially available paclitaxel will be administrated as IV infusion over 3 hours once every 3 weeks.
Study: NCT03792555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paltusotine
Description: Paltusotine, capsules, once daily by mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, capsules, once daily by mouth
Study: NCT03203577

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Initiation of mechanical ventilation
Description: In patient with chronic respiratory insufficient chronic mechanical ventilation will be initiated in the patient his/her setting.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Initiation of mechanical ventilation
Description: In patient with chronic respiratory insufficient chronic mechanical ventilation will be initiated in the patient his/her setting.
Study: NCT01789086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Administered subcutaneously (s.c., under skin) for 5-6 weeks. Initial dose of 0.6 mg/day. The dose will be escalated by 0.6 mg/day in weekly steps to a maximum of 3.0 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered subcutaneously (s.c., under skin) for 5-6 weeks. Initial dose of 0.6 mg/day. The dose will be escalated by 0.6 mg/day in weekly steps to a maximum of 3.0 mg/day
Study: NCT02448992

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hippocampal-sparing WBRT
Study: NCT04744220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Training Program (exercises)
Description: Training: Before the yoga program, the patients will be informed about the bronchiectasis disease and its symptoms, as well as all the parameters used in the evaluation, tests and the content of the yoga session. The patients will start with breathing exercises, then relaxation exercises, warm-up exercises, asanas (posture exercises) and finally the yoga training program will be completed with deep relaxation technique.